Triple-negative breast cancer is a tough diagnosis because it lacks common treatment targets. Doctors often struggle to predict which patients will have a recurrence versus those who will do well. This research looked for a genetic clue hidden in the tumor itself to help answer that question sooner.
The team analyzed data from large public databases and tested their findings on real clinical samples. They found that a specific set of genes acted like a warning system. These genes were mostly active in immune cells called T cells, which fight the cancer. The study mapped how these cells change over time and how they talk to other immune cells like macrophages to coordinate a defense.
When they checked the actual proteins in the tissue, they saw a clear pattern. High levels of certain proteins, like GZMB and RSPO3, were linked to lower risk of the cancer coming back. Conversely, high levels of other proteins predicted a higher chance of recurrence and poorer survival. This distinction could eventually help doctors tailor care to each patient's specific biology.